beta
/802P Nous-209 immunotherapy with pembrolizumab for microsatellite instability high (MSI-H) metastatic colorectal cancer, refractory to anti-PD-1: Phase II trial results

Reviews

Join the dialogue

Submit a peer review to improve the scientific record

Summary